Taiwan's biotechnology industry is poised to cash in on drugs developed from traditional Chinese herbal remedies, experts said yesterday.
"In Taiwan, we are doing good research in Chinese herbal rem-edies, but now we need to commercialize," Winston Town (湯竣鈞), chief operating officer of herbal drug developer Cathay Biotech Co (中華公明生物科技), told the Taipei Times yesterday.
In order to turn research investments into big bucks, companies have to prove scientifically that Chinese herbal remedies work, and the only way to do that is to present them for approval to regulatory authorities in the US, Europe and Japan, Town said.
Taiwan is banking on biotechnology and other advanced industries to replace manufacturing that has now moved to low-cost China.
In May of last year, President Chen Shui-bian (
Exploiting the nation's cultural heritage could help biotech companies to produce their own uniquely Chinese drugs.
"Traditional Chinese medicine offers excellent opportunities for Taiwanese biotechnology companies," said Jerry Chen (
Only last Friday Chen's office hosted a business opportunities forum for companies interested in developing drugs from Chinese herbs, and over 100 people attended, Chen said.
The government has funded three research centers to look specifically at herb-based drugs, the Development Center for Biotechnology in Taipei, the Pharmaceutical Industry Technology and Development Center in Taipei County and the Biomedical Engineering Center at the Industrial Technology Research Institute in Hsinchu.
But research is not enough.
"There is a huge amount of potential for Taiwanese companies through herbal medicine," said David Silver, director of Biotech-east.com, a Web site that promotes Taiwan's biotechnology and pharmaceutical industries. "But there are problems with patentability and regulations."
Companies cannot claim a patent on naturally occurring plants, but they can patent an effective chemical compound extracted from a plant that they have isolated, or present a mixture of herbs to regulatory authorities in the US, Europe and Japan and ask for approval.
To do this, they need to have carried out quality control tests and be able to guarantee consistent dosages, Silver said.
Isolating one compound in an herb is a very difficult process that involves a lot of computing power and time, Silver said, but it is very lucrative if successful. Presenting an herbal mix for approval is much simpler, and is now possible after US Food and Drug Administration rules were changed last year.
That is exactly what Cathay is doing with a mixture of 15 different Chinese herbs that it claims from its own preliminary trials can treat sufferers of Hepatitis B and HIV.
On the strength of this research, Cathay submitted an application to the FDA for its multi-herb treatment and had it accepted, Town said yesterday.
Town expects the second phase of clinical trials to be completed and approved within 12 months. After that, Cathay can sell licenses for its treatment to global pharmaceutical companies who have the resources to complete the third and final phase of trials before marketing the drug globally.
Other Taiwanese companies could follow this route.
"Our business model works," Cathay's chairman, David Wu (
While awaiting FDA approval Cathay is exploring other avenues, Wu added. In Taiwan, Cathay's approved over-the-counter liver tonic, called YGK (
If successful, the drug would be paid for by international humanitarian donations.
DEVELOPING TALENT: The electronics contractor is looking to recruit people to work in core tech fields and emerging industries like electric cars and robotics Hon Hai Precision Industry Co (鴻海精密), the world’s largest contract electronics maker, has launched a recruitment drive, offering a monthly salary of no less than NT$45,000 (US$1,485) to university graduates. For those with a master’s degree, the starting pay would be NT$52,000 per month at the minimum, while doctorate degree holders would receive at least NT$60,000 a month, Hon Hai said a statement issued early this week. The latest recruitment drive is aimed at attracting talent in core technology fields — artificial intelligence, semiconductors and next-generation mobile communications — and emerging industries — electric vehicles, digital healthcare and robotics, the
MRT TRAVEL FALLS: In February, ridership on the Taipei MRT System fell 8.96 percent from an average of 2.01 million per day in January Scooter sales jumped 13 percent last month as more commuters turned to two-wheelers to avoid public transportation amid the COVID-19 pandemic, the latest statistics showed. Sales expanded to 74,493 units last month, compared with 65,913 units in February, statistics released on Wednesday by Kwang Yang Motor Co (光陽工業) and the Ministry of Transportation and Communications showed. In the first quarter, aggregate sales slid 0.51 percent year-over-year to 186,627 units, from 187,580 units, data showed. Kwang Yang, the nation’s biggest scooter manufacturer, continued to lead the market by selling 24,136 vehicles last month, growing 6.12 percent from 20,785 units in the previous month, while
Asustek Computer Inc (華碩), the nation’s leading PC vendor, yesterday launched its first dual-screen gaming laptop powered by Intel Corp’s latest central processing units (CPUs). The PC manufacturer’s announcement closely followed the US chipmaker’s unveiling of its 10th Generation Core H-series, the fastest commercial mobile processors with speeds of up to 5 gigahertz. Although Asustek’s Zephyrus Duo 15, the highlight of its Republic of Gamers line, is not the company’s first laptop with two screens, it is its first designed specifically for gaming. Nestled between the primary display panel and the keyboard, the secondary display, which Asustek calls the ScreenPad Plus, is angled
NO ILL EFFECT: Last month’s data mainly reflected deals made in February, when the spread of COVID-19 was still relatively mild in Taiwan, housing brokers said Housing transactions in the six special municipalities totaled 19,824 units last month, up 7.8 percent from a year earlier, brokers said, citing government data. Last month’s data mainly reflected deals made in February, when the pinch of the COVID-19 pandemic was not yet evident, they said. Taoyuan posted the largest improvement, with housing transactions soaring 36.6 percent year-on-year to 3,676 units, local government data showed. Taiwan Realty Co (台灣房屋) attributed the pickup to the completion of two presale residential projects in the municipality. Houses in Taoyuan have increasingly gained in popularity in the past few year years due to relatively affordable home prices and